Literature DB >> 29684500

The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.

Nozomu Kurose1, Chizuru Futatsuya1, Ken-Ichi Mizutani1, Motona Kumagai1, Akihiro Shioya1, Xin Guo1, Akane Aikawa1, Satoko Nakada1, Shino Fujimoto2, Hiroshi Kawabata2, Yasufumi Masaki2, Kazue Takai3, Sadao Aoki4, Masaru Kojima5, Shigeo Nakamura6, Sohsuke Yamada7.   

Abstract

Multicentric Castleman disease (MCD) is a systemic inflammatory disease potentially caused by an increase in the serum interleukin-6 (IL-6) level. Idiopathic MCD (iMCD) is histopathologically classified into three types: plasmacytic (PC), mixed, and hypervascular (hyperV) types. Recently, a unique clinical phenotype with a poor prognosis overlap with iMCD, thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly (TAFRO syndrome), has been reported from Japan, but its detailed clinicopathological features remain unclear. In this study, we performed a clinicopathological analysis of 70 nodal cases of iMCD with and without TAFRO syndrome (n = 37 versus n = 33). Compared with iMCD without TAFRO, iMCD with TAFRO showed more atrophic lymphoid follicles (LF), greater distances between follicles, increased glomeruloid vascular proliferation within the germinal center, and increased follicular dendritic cells. In addition, the hyperV type in particular demonstrated severe atrophic LF and interfollicular vascular proliferation. Among the mixed-type cases, the serum IL-6 levels in iMCD with TAFRO were significantly higher than those in iMCD without TAFRO. Furthermore, compared to iMCD without TAFRO, the numbers of immunoglobulin G4 (IgG4)-positive and CD38-positive plasma cells were significantly decreased in iMCD with TAFRO.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Creatinine (Cre); Follicular dendritic cell (FDC), interleukin-6 (IL-6); Idiopathic multicentric Castleman disease (iMCD); Immunoglobulin G4 (IgG4); TAFRO syndrome

Mesh:

Substances:

Year:  2018        PMID: 29684500     DOI: 10.1016/j.humpath.2018.04.001

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  3 in total

1.  Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population.

Authors:  Karen M Chisholm; Mark D Fleming
Journal:  Am J Clin Pathol       Date:  2020-05-05       Impact factor: 2.493

2.  Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Shino Fujimoto; Mitsuhiro Kawano; Noriko Iwaki; Takeharu Kotani; Akikatsu Nakashima; Nozomu Kurose; Kazue Takai; Ritsuro Suzuki; Sadao Aoki
Journal:  J Clin Exp Hematop       Date:  2019-11-08

Review 3.  Castleman disease and TAFRO syndrome.

Authors:  Yasufumi Masaki; Kotaro Arita; Tomoyuki Sakai; Kazue Takai; Sadao Aoki; Hiroshi Kawabata
Journal:  Ann Hematol       Date:  2022-01-19       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.